Andrew Allen Acquires Shares of Cullinan Therapeutics

On June 16, 2026, Andrew Allen purchased 21,781 shares of Cullinan Therapeutics, Inc. (NasdaqGS: CGEM). The transaction was not part of a pre-planned trading strategy and occurred as the stock traded near $14.44.

Insider Buying and Selling at Cullinan Therapeutics, Inc.

Andrew Allen's purchase was part of a series of insider buys on the same date. Other insiders, including Doyle Mittie, Mary Thistle, David Meek, Stephen Webster, and Anthony Rosenberg, each acquired shares in similar amounts, highlighting a wave of insider confidence in the company.

Other Institutional Activity in Cullinan Therapeutics

Institutional investors have shown varied interest in Cullinan Therapeutics. BlackRock, Inc. increased its holdings by 49,670 shares, bringing its total to 4,449,966 shares worth about $63.2 million. State Street Corp also increased its stake by 346,777 shares to a total of 2,544,115 shares, valued at approximately $36.2 million. Meanwhile, other funds like LYNX1 Capital Management LP, MPM BioImpact LLC, and BVF Inc/IL maintained their positions without change.

Cullinan Therapeutics Stock Snapshot

Shares of Cullinan Therapeutics, Inc. are currently trading near $14.44. The company has a market cap of approximately $887.5 million and a beta of 0.007, indicating low volatility. Over the past 52 weeks, the stock has ranged from $5.68 to $16.74. It has a 50-day moving average of $14.43 and a 200-day moving average of $11.38. The company has a strong current ratio of 10.28, suggesting robust liquidity.

Analysts Set New Price Targets

Analyst sentiment remains positive for Cullinan Therapeutics, with several firms reiterating their buy ratings. On June 11, 2026, Wedbush reiterated its buy rating with a price target of $37. BTIG also maintained its buy rating with a target of $38 on April 29, 2026. The consensus among 11 analysts is a strong buy, with a mean target price of $31.55.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing therapies for autoimmune diseases and cancer. The company is advancing several clinical-stage programs, including CLN-978 for autoimmune diseases and CLN-049 for acute myeloid leukemia. Led by CEO Nadim Ahmed, Cullinan Therapeutics seeks to address unmet medical needs through innovative treatments.

Bottom Line

Andrew Allen's recent purchase of Cullinan Therapeutics shares reflects insider confidence in the company's future prospects. As a clinical-stage biotech firm, Cullinan is closely watched by investors for its potential breakthroughs in cancer and autoimmune therapies. The stock's recent activity, coupled with strong analyst endorsements, positions it as a noteworthy player in the healthcare sector.